Podcasts about great debates

Dr. Linda Duska and Dr. Kathleen Moore discuss key studies in the evolving controversy over radical upfront surgery versus neoadjuvant chemotherapy in advanced ovarian cancer. TRANSCRIPT Dr. Linda Duska: Hello, and welcome to the ASCO Daily News Podcast. I am your guest host, Dr. Linda Duska. I am a professor of obstetrics and gynecology at the University of Virginia School of Medicine.  On today's episode, we will explore the management of advanced ovarian cancer, specifically with respect to a question that has really stirred some controversy over time, going all the way back more than 20 years: Should we be doing radical upfront surgery in advanced ovarian cancer, or should we be doing neoadjuvant chemotherapy? So, there was a lot of hype about the TRUST study, also called ENGOT ov33/AGO-OVAR OP7, a Phase 3 randomized study that compares upfront surgery with neoadjuvant chemotherapy followed by interval surgery. So, I want to talk about that study today. And joining me for the discussion is Dr. Kathleen Moore, a professor also of obstetrics and gynecology at the University of Oklahoma and the deputy director of the Stephenson Cancer Center, also at the University of Oklahoma Health Sciences.  Dr. Moore, it is so great to be speaking with you today. Thanks for doing this. Dr. Kathleen Moore: Yeah, it's fun to be here. This is going to be fun. Dr. Linda Duska: FYI for our listeners, both of our full disclosures are available in the transcript of this episode.  So let's just jump right in. We already alluded to the fact that the TRUST study addresses a question we have been grappling with in our field. Here's the thing, we have four prior randomized trials on this exact same topic. So, share with me why we needed another one and what maybe was different about this one? Dr. Kathleen Moore: That is, I think, the key question. So we have to level-set kind of our history. Let's start with, why is this even a question? Like, why are we even talking about this today? When we are taking care of a patient with newly diagnosed ovarian cancer, the aim of surgery in advanced ovarian cancer ideally is to prolong a patient's likelihood of disease-free survival, or if you want to use the term "remission," you can use the term "remission." And I think we can all agree that our objective is to improve overall survival in a way that also does not compromise her quality of life through surgical complications, which can have a big effect. The standard for many decades, certainly my entire career, which is now over 20 years, has been to pursue what we call primary cytoreductive surgery, meaning you get a diagnosis and we go right to the operating room with a goal of achieving what we call "no gross residual." That is very different – in the olden days, you would say "optimal" and get down to some predefined small amount of tumor. Now, the goal is you remove everything you can see.  The alternative strategy to that is neoadjuvant chemotherapy followed by interval cytoreductive surgery, and that has been the, quote-unquote, "safer" route because you chemically cytoreduce the cancer, and so, the resulting surgery, I will tell you, is not necessarily easy at all. It can still be very radical surgeries, but they tend to be less radical, less need for bowel resections, splenectomy, radical procedures, and in a short-term look, would be considered safer from a postoperative consideration. Dr. Linda Duska: Well, and also maybe more likely to be successful, right? Because there's less disease, maybe, theoretically. Dr. Kathleen Moore: More likely to be successful in getting to no gross residual. Dr. Linda Duska: Right. Yeah, exactly. Dr. Kathleen Moore: I agree with that. And so, so if the end game, regardless of timing, is you get to no gross residual and you help a patient and there's no difference in overall survival, then it's a no-brainer. We would not be having this conversation. But there remains a question around, while it may be more likely to get to no gross residual, it may be, and I think we can all agree, a less radical, safer surgery, do you lose survival in the long term by this approach? This has become an increasing concern because of the increase in rates of use of neoadjuvant, not only in this country, but abroad. And so, you mentioned the four prior studies. We will not be able to go through them completely. Dr. Linda Duska: Let's talk about the two modern ones, the two from 2020 because neither one of them showed a difference in overall survival, which I think we can agree is, at the end of the day, yes, PFS would be great, but OS is what we're looking for. Dr. Kathleen Moore: OS is definitely what we're looking for. I do think a marked improvement in PFS, like a real prolongation in disease-free survival, for me would be also enough. A modest improvement does not really cut it, but if you are really, really prolonging PFS, you should see that-  Dr. Linda Duska: -manifest in OS. Dr. Kathleen Moore: Yeah, yeah. Okay. So let's talk about the two modern ones. The older ones are EORTC and CHORUS, which I think we've talked about. The two more modern ones are SCORPION and JCOG0602. So, SCORPION was interesting. SCORPION was a very small study, though. So one could say it's underpowered. 170 patients. And they looked at only patients that were incredibly high risk. So, they had to have a Fagotti score, I believe, of over 9, but they were not looking at just low volume disease. Like, those patients were not enrolled in SCORPION. It was patients where you really were questioning, "Should I go to the OR or should I do neoadjuvant? Like, what's the better thing?" It is easy when it's low volume. You're like, "We're going." These were the patients who were like, "Hm, you know, what should I do?" High volume. Patients were young, about 55. The criticism of the older studies, there are many criticisms, but one of them is that, the criticism that is lobbied is that they did not really try. Whatever surgery you got, they did not really try with median operative times of 180 minutes for primary cytoreduction, 120 for neoadjuvant. Like, you and I both know, if you're in a big primary debulking, you're there all day. It's 6 hours. Dr. Linda Duska: Right, and there was no quality control for those studies, either. Dr. Kathleen Moore: No quality control. So, SCORPION, they went 451-minute median for surgery. Like, they really went for it versus four hours and then 253 for the interval, 4 hours. They really went for it on both arms. Complete gross resection was achieved in 50% of the primary cytoreduced. So even though they went for it with these very long surgeries, they only got to the goal half the time. It was almost 80% in the interval group. So they were more successful there. And there was absolutely no difference in PFS or OS. They were right about 15 months PFS, right about 40 months OS.  JCOG0602, of course, done in Japan, a big study, 300 patients, a little bit older population. Surprisingly more stage IV disease in this study than were in SCORPION. SCORPION did not have a lot of stage IV, despite being very bulky tumors. So a third of patients were stage IV. They also had relatively shorter operative times, I would say, 240 minutes for primary, 302 for interval. So still kind of short. Complete gross resection was not achieved very often. 30% of primary cytoreduction. That is not acceptable. Dr. Linda Duska: Well, so let's talk about TRUST. What was different about TRUST? Why was this an important study for us to see? Dr. Kathleen Moore: So the criticism of all of these, and I am not trying to throw shade at anyone, but the criticism of all of these is if you are putting surgery to the test, you are putting the surgeon to the test. And you are assuming that all surgeons are trained equally and are willing to do what it takes to get someone to no gross residual. Dr. Linda Duska: And are in a center that can support the post-op care for those patients. Dr. Kathleen Moore: Which can be ICU care, prolonged time. Absolutely. So when you just open these broadly, you're assuming everyone has the surgical skills and is comfortable doing that and has backup. Everybody has an ICU. Everyone has a blood bank, and you are willing to do that. And that assumption could be wrong. And so what TRUST said is, "Okay, we are only going to open this at centers that have shown they can achieve a certain level of primary cytoreduction to no gross residual disease." And so there was quality criteria. It was based on – it was mostly a European study – so ESGO criteria were used to only allow certified centers to participate. They had to have a surgical volume of over 36 cytoreductive surgeries per year. So you could not be a low volume surgeon. Your complete resection rates that were reported had to be greater than 50% in the upfront setting. I told you on the JCOG, it was 30%. Dr. Linda Duska: Right. So these were the best of the best. This was the best possible surgical situation you could put these patients in, right? Dr. Kathleen Moore: Absolutely. And you support all the things so you could mitigate postoperative complications as well. Dr. Linda Duska: So we are asking the question now again in the ideal situation, right? Dr. Kathleen Moore: Right. Dr. Linda Duska: Which, we can talk about, may or may not be generalizable to real life, but that's a separate issue because we certainly don't have those conditions everywhere where people get cared for with ovarian cancer. But how would you interpret the results of this study? Did it show us anything different? Dr. Kathleen Moore: I am going to say how we should interpret it and then what I am thinking about. It is a negative study. It was designed to show improvement in overall survival in these ideal settings in patients with FIGO stage IIIB and C, they excluded A, these low volume tumors that should absolutely be getting surgery. So FIGO stage IIIB and C and IVA and B that were fit enough to undergo radical surgery randomized to primary cytoreduction or neoadjuvant with interval, and were all given the correct chemo. Dr. Linda Duska: And they were allowed bevacizumab and PARP, also. They could have bevacizumab and PARP. Dr. Kathleen Moore: They were allowed bevacizumab and PARP. Not many of them got PARP, but it was distributed equally, so that would not be a confounder. And so that was important. Overall survival is the endpoint. It was a big study. You know, it was almost 600 patients. So appropriately powered. So let's look at what they reported. When they looked at the patients who were enrolled, this is a large study, almost 600 patients, 345 in the primary cytoreductive arm and 343 in the neoadjuvant arm. Complete resection in these patients was 70% in the primary cytoreductive arm and 85% in the neoadjuvant arm. So in both arms, it was very high. So your selection of site and surgeon worked. You got people to their optimal outcome. So that is very different than any other study that has been reported to date. But what we saw when we looked at overall survival was no statistical difference. The median was, and I know we do not like to talk about medians, but the median in the primary cytoreductive arm was 54 months versus 48 months in the neoadjuvant arm with a hazard ratio of 0.89 and, of course, the confidence interval crossed one. So this is not statistically significant. And that was the primary endpoint. Dr. Linda Duska: I know you are getting to this. They did look at PFS, and that was statistically significant, but to your point about what are we looking for for a reasonable PFS difference? It was about two months difference. When I think about this study, and I know you are coming to this, what I thought was most interesting about this trial, besides the fact that the OS, the primary endpoint was negative, was the subgroup analyses that they did. And, of course, these are hypothesis-generating only. But if you look at, for example, specifically only the stage III group, that group did seem to potentially, again, hypothesis generating, but they did seem to benefit from upfront surgery.  And then one other thing that I want to touch on before we run out of time is, do we think it matters if the patient is BRCA germline positive? Do we think it matters if there is something in particular about that patient from a biomarker standpoint that is different? I am hopeful that more data will be coming out of this study that will help inform this. Of course, unpowered, hypothesis-generating only, but it's just really interesting. What do you think of their subset analysis? Dr. Kathleen Moore: Yeah, I think the subsets are what we are going to be talking about, but we have to emphasize that this was a negative trial as designed. Dr. Linda Duska: Absolutely. Yes. Dr. Kathleen Moore: So we cannot be apologists and be like, "But this or that." It was a negative trial as designed. Now, I am a human and a clinician, and I want what is best for my patients. So I am going to, like, go down the path of subset analyses. So if you look at the stage III tumors that got complete cytoreduction, which was 70% of the cases, your PFS was almost 28 months versus 21.8 months. Dr. Linda Duska: Yes, it becomes more significant. Dr. Kathleen Moore: Yeah, that hazard ratio is 0.69. Again, it is a subset. So even though the P value here is statistically significant, it actually should not have a P value because it is an exploratory analysis. So we have to be very careful. But the hazard ratio is 0.69. So the hypothesis is in this setting, if you're stage III and you go for it and you get someone to no gross residual versus an interval cytoreduction, you could potentially have a 31% reduction in the rate of progression for that patient who got primary cytoreduction. And you see a similar trend in the stage III patients, if you look at overall survival, although the post-progression survival is so long, it's a little bit narrow of a margin.  But I do think there are some nuggets here that, one of our colleagues who is really one of the experts in surgical studies, Dr. Mario Leitao, posted this on X, and I think it really resonated after this because we were all saying, "But what about the subsets?" He is like, "It's a negative study." But at the end of the day, you are going to sit with your patient. The patient should be seen by a GYN oncologist or surgical oncologist with specialty in cytoreduction and a medical oncologist, you know, if that person does not give chemo, and the decision should be made about what to do for that individual patient in that setting. Dr. Linda Duska: Agreed. And along those lines, if you look carefully at their data, the patients who had an upfront cytoreduction had almost twice the risk of having a stoma than the patients who had an interval cytoreduction. And they also had a higher risk of needing to have a bowel resection. The numbers were small, but still, when you look at the surgical complications, as you've already said, they're higher in the upfront group than they are in the interval group. That needs to be taken into account as well when counseling a patient, right? When you have a patient in front of you who says to you, "Dr. Moore, you can take out whatever you want, but whatever you do, don't make me a bag." As long as the patient understands what that means and what they're asking us to do, I think that we need to think about that. Dr. Kathleen Moore: I think that is a great point. And I have definitely seen in our practice, patients who say, "I absolutely would not want an ostomy. It's a nonstarter for me." And we do make different decisions. And you have to just say, "That's the decision we've made," and you kind of move on, and you can't look back and say, "Well, I wish I would have, could have, should have done something else." That is what the patient wants. Ultimately, that patient, her family, autonomous beings, they need to be fully counseled, and you need to counsel that patient as to the site that you are in, her volume of disease, and what you think you can achieve. In my opinion, a patient with stage III cancer who you have the site and the capabilities to get to no gross residual should go to the OR first. That is what I believe. I do not anymore think that for stage IV. I think that this is pretty convincing to me that that is probably a harmful thing. However, I want you to react to this. I think I am going to be a little unpopular in saying this, but for me, one of the biggest take-homes from TRUST was that whether or not, and we can talk about the subsets and the stage III looked better, and I think it did, but both groups did really well. Like, really well. And these were patients with large volume disease. This was not cherry-picked small volume stage IIIs that you could have done an optimal just by doing a hysterectomy. You know, these were patients that needed radical surgery. And both did well. And so what it speaks to me is that anytime you are going to operate on someone with ovary, whether it be frontline, whether it be a primary or interval, you need a high-volume surgeon. That is what I think this means to me. Like, I would want high volume surgeon at a center that could do these surgeries, getting that patient, my family member, me, to no gross residual. That is important. And you and I are both in training centers. I think we ought to take a really strong look at, are we preparing people to do the surgeries that are necessary to get someone to no gross residual 70% and 85% of the time? Dr. Linda Duska: We are going to run out of time, but I want to address that and ask you a provocative question. So, I completely agree with what you said, that surgery is important. But I also think one of the reasons these patients in this study did so well is because all of the incredible new therapies that we have for patients. Because OS is not just about surgery. It is about surgery, but it is also about all of the amazing new therapies we have that you and others have helped us to get through clinical research. And so, how much of that do you think, like, for example, if you look at the PFS and OS rates from CHORUS and EORTC, I get it that they're, that they're not the same. It's different patients, different populations, can't do cross-trial comparisons. But the OS, as you said, in this study was 54 months and 48 months, which is, compared to 2010, we're doing much, much better. It is not just the surgery, it is also all the amazing treatment options we have for these patients, including PARP, including MIRV, including lots of other new therapies. How do you fit that into thinking about all of this? Dr. Kathleen Moore: I do think we are seeing, and we know this just from epidemiologic data that the prevalence of ovarian cancer in many of the countries where the study was done is increasing, despite a decrease in incidence. And why is that? Because people are living longer. Dr. Linda Duska: People are living longer, yeah. Dr. Kathleen Moore: Which is phenomenal. That is what we want. And we do have, I think, better supportive care now. PARP inhibitors in the frontline, which not many of these patients had. Now some of them, this is mainly in Europe, will have gotten them in the first maintenance setting, and I do think that impacts outcome. We do not have that data yet, you know, to kind of see what, I would be really interested to see. We do not do this well because in ovarian cancer, post-progression survival can be so long, we do not do well of tracking what people get when they come off a clinical trial to see how that could impact – you know, how many of them got another surgery? How many of them got a PARP? I think this group probably missed the ADC wave for the most part, because this, mirvetuximab is just very recently available in Europe. Dr. Linda Duska: Unless they were on trial. Dr. Kathleen Moore: Unless they were on trial. But I mean, I think we will have to see. 600 patients, I would bet a lot of them missed the ADC wave. So, I do not know that we can say we know what drove these phenomenal – these are some of the best curves we've seen outside of BRCA. And then coming back to your point about the BRCA population here, that is a really critical question that I do not know that we're ever going to answer. There have been hypotheses around a tumor that is driven by BRCA, if you surgically cytoreduced it, and then chemically cytoreduced it with chemo, and so you're starting PARP with nothing visible and likely still homogeneous clones. Is that the group we cured? And then if you give chemo first before surgery, it allows more rapid development of heterogeneity and more clonal evolution that those are patients who are less likely to be cured, even if they do get cytoreduced to nothing at interval with use of PARP inhibitor in the front line. That is a question that many have brought up as something we would like to understand better. Like, if you are BRCA, should you always just go for it or not? I do not know that we're ever going to really get to that. We are trying to look at some of the other studies and just see if you got neoadjuvant and you had BRCA, was anyone cured? I think that is a question on SOLO1 I would like to know the answer to, and I don't yet, that may help us get to that. But that's sort of something we do think about. You should have a fair number of them in TRUST. It wasn't a stratification factor, as I remember. Dr. Linda Duska: No, it wasn't. They stratified by center, age, and ECOG status Dr. Kathleen Moore: So you would hope with randomization that you would have an equal number in each arm. And they may be able to pull that out and do a very exploratory look. But I would be interested to see just completely hypothesis-generating what this looks like for the patients with BRCA, and I hope that they will present that. I know they're busy at work. They have translational work. They have a lot pending with TRUST. It's an incredibly rich resource that I think is going to teach us a lot, and I am excited to see what they do next. Dr. Linda Duska: So, outside of TRUST, we are out of time. I just want to give you a moment if there were any other messages that you want to share with our listeners before we wrap up. Dr. Kathleen Moore: It's an exciting time to be in GYN oncology. For so long, it was just chemo, and then the PARP inhibitors nudged us along quite a bit. We did move more patients, I believe, to the cure fraction. When we ultimately see OS, I think we'll be able to say that definitively, and that is exciting. But, you know, that is the minority of our patients. And while HRD positive benefits tremendously from PARP, I am not as sure we've moved as many to the cure fraction. Time will tell. But 50% of our patients have these tumors that are less HRD. They have a worse prognosis. I think we can say that and recur more quickly. And so the advent of these antibody-drug conjugates, and we could name 20 of them in development in GYN right now, targeting tumor-associated antigens because we're not really driven by mutations other than BRCA. We do not have a lot of things to come after. We're not lung cancer. We are not breast cancer. But we do have a lot of proteins on the surface of our cancers, and we are finally able to leverage that with some very active regimens. And we're in the early phases, I would say, of really understanding how best to use those, how best to position them, and which one to select for whom in a setting where there is going to be obvious overlap of the targets. So we're going to be really working this problem. It is a good problem. A lot of drugs that work pretty well. How do you individualize for a patient, the patient in front of you with three different markers? How do you optimize it? Where do you put them to really prolong survival? And then we finally have cell surface. We saw at ASCO, CDK2 come into play here for the first time, we've got a cell cycle inhibitor. We've been working on WEE1 and ATR for a long time. CDK2s may hit. Response rates were respectable in a resistant population that was cyclin E overexpressing. We've been working on that biomarker for a long time with a toxicity profile that was surprisingly clean, which I like to see for our patients. So that is a different platform. I think we have got bispecifics on the rise. So there is a pipeline of things behind the ADCs, which is important because we need more than one thing, that makes me feel like in the future, I am probably not going to be using doxil ever for platinum-resistant disease. So, I am going to be excited to retire some of those things. We will say, "Remember when we used to use doxil for platinum-resistant disease?" Dr. Linda Duska: I will be retired by then, but thanks for that thought. Dr. Kathleen Moore: I will remind you. Dr. Linda Duska: You are right. It is such an incredibly exciting time to be taking care of ovarian cancer patients with all the opportunities.  And I want to thank you for sharing your valuable insights with us on this podcast today and for your great work to advance care for patients with GYN cancers. Dr. Kathleen Moore: Likewise. Thanks for having me. Dr. Linda Duska: And thank you to our listeners for your time today. You will find links to the TRUST study and other studies discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:   Dr. Linda Duska  @Lduska Dr. Kathleen Moore Follow ASCO on social media:     @ASCO on X (formerly Twitter) ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures of Potential Conflicts of Interest:    Dr. Linda Duska:   Consulting or Advisory Role: Regeneron, Inovio Pharmaceuticals, Merck, Ellipses Pharma  Research Funding (Inst.): GlaxoSmithKline, Millenium, Bristol-Myers Squibb, Aeterna Zentaris, Novartis, Abbvie, Tesaro, Cerulean Pharma, Aduro Biotech, Advaxis, Ludwig Institute for Cancer Research, Leap Therapeutics  Patents, Royalties, Other Intellectual Property: UptToDate, Editor, British Journal of Ob/Gyn  Dr. Kathleen Moore: Leadership: GOG Partners, NRG Ovarian Committee Chair Honoraria: Astellas Medivation, Clearity Foundation, IDEOlogy Health, Medscape, Great Debates and Updates, OncLive/MJH Life Sciences, MD Outlook, Curio Science, Plexus, University of Florida, University of Arkansas for Medical Sciences, Congress Chanel, BIOPHARM, CEA/CCO, Physician Education Resource (PER), Research to Practice, Med Learning Group, Peerview, Peerview, PeerVoice, CME Outfitters, Virtual Incision Consulting/Advisory Role: Genentech/Roche, Immunogen, AstraZeneca, Merck, Eisai, Verastem/Pharmacyclics, AADi, Caris Life Sciences, Iovance Biotherapeutics, Janssen Oncology, Regeneron, zentalis, Daiichi Sankyo Europe GmbH, BioNTech SE, Immunocore, Seagen, Takeda Science Foundation, Zymeworks, Profound Bio, ADC Therapeutics, Third Arc, Loxo/Lilly, Bristol Myers Squibb Foundation, Tango Therapeutics, Abbvie, T Knife, F Hoffman La Roche, Tubulis GmbH, Clovis Oncology, Kivu, Genmab/Seagen, Kivu, Genmab/Seagen, Whitehawk, OnCusp Therapeutics, Natera, BeiGene, Karyopharm Therapeutics, Day One Biopharmaceuticals, Debiopharm Group, Foundation Medicine, Novocure Research Funding (Inst.): Mersana, GSK/Tesaro, Duality Biologics, Mersana, GSK/Tesaro, Duality Biologics, Merck, Regeneron, Verasatem, AstraZeneca, Immunogen, Daiichi Sankyo/Lilly, Immunocore, Torl Biotherapeutics, Allarity Therapeutics, IDEAYA Biosciences, Zymeworks, Schrodinger Other Relationship (Inst.): GOG Partners

Hard to keep a lawn down at the moment.PLENTY happening as per usual. Updates on some ripper content and our plan to catch up with some legends in Melbourne for the Supercross. The Great Debate of Whippersnipping VS Poisoning is discussed before we rip in to the usual segments, Trip Advisor reviews are prime during Pub Of The Week. Are Elons robots on the rise? We discuss during the news, as well as recapping UFC 322. An absolute gold mine during Pep & Poo's Dump Finds For You before bringing it home with a Playboy edition during Poo's Reviews. Enjoy the rest of your week trendsetters, stay outta yaself!The ABW Bucking Bull Of The Year Shirt Pre-Sale begins Saturday, 6PM and runs until Friday, the 28th: alphablokes.com.auEver wanted to watch the Podcast? Check out full visual, uncut and ad-free versions on our Patreon. Only $5 a week plus access to all of our exclusive vlogs. The Four Part Darwin series begins this Sunday: patreon.com/alphablokespodcastBetter Beer: Jog in a can, win in a tin, the athletes choice: https://www.betterbeer.com.au/Neds: Whatever you bet on, take it to the neds level: https://www.neds.com.au/SP Tools: Schmicker tools for an even schmicker price, use code "ALPHA" at checkout for 10% off and check out their brand new catalogue: sptools.comIf you want to keep up to date with what we're up to, the best way is to follow us on the socials down below:PODCAST INSTAGRAM: www.instagram.com/alphablokespodcast/PODCAST TIKTOK: https://www.tiktok.com/@alphablokespodcastPODCAST FACEBOOK: https://www.facebook.com/alphablokespodcast/Follow the boys on Instagram to check out their solo content too:Tommy: https://www.instagram.com/tomdahl_/Bandit: https://www.instagram.com/_thepoobandit_/0:00 - Admin + Updates8:00 - ABW Shirt Presale10:30 - Alpha Stable15:00 - Weekends41:25 - Pub Of The Week46:59 - Cooking / Eating55:27 - Alpha News1:26:22 - Motivation1:38:23 - Pep & Poo's Dump Finds For You1:45:14 - Poo's Reviews Hosted on Acast. See acast.com/privacy for more information.

The First Sparring Of The Great Debate The first sparring of The Great Debate takes place here with the Christian & atheist getting five questions to ask for the other to answer. While we aren't used to this format, this really lays out the needed back and forth interaction that a lot of debates lack within a formal structure. It's not the blood-sport debates we're used to on YouTube but it helps with each side making sure the other is interacting with their points the best. TIMELINE: 00:00 - Introduction 03:22 - Q1 - Source For Atheism Definition 04:03 - A1 - Source Cited 05:15 - Q2 - Cite The Argument Used By Bahnsen 05:36 - A2 - No But You Believe It 06:49 - Q3 - Where's The Transcendental Argument 07:50 - A3 - No Because It's Not A Proof 08:12 - Commentary - Stein Was Helpful For Presuppositionalists 10:49 - Q4 - All Questions Answered The Same Way 11:08 - A4 - No They Are Not 11:34 - Q5 & A5 - What Does An Atheist Believe Laws Of Logic Are 14:21 - Atheist 14:41 - Q1 & Q2 - The Nature Of God 17:04 - Q2 & A2 - Is Your God All The Omnis 17:33 - Q3 & Q3 - If Argument Is Wrong Will God Not Exist 17:56 - Commentary - A Clarifying Comment On A "Problematic" Bahnsen 20:25 - Q4 & A4 - Is God Good 24:43 - Q5 & A5 - Can You Prove The Soul 26:38 - Conclusion BOOK LINKS: The Great Debate - Does God Exist? - Edited and Commentary by Joshua Pillows Debate Transcript Video The Bahnsen Institute       All episodes, short clips, & blog - https://www.cavetothecross.com

Bush Hager and Bibb take turns defending their sides on fun topics in “The Great Debate.” Also, actress Ali Larter stops by to discuss the new season of “Landman”, where she plays the feisty Angela navigating the world of Texas oil. Plus, learn how to refurbish and update old desks, chairs, and other furniture pieces. And, beauty expert Michelle Park and dermatologist Dr. David Kim break down the hottest K-beauty trends and reveal treatments that really work. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this new episode of Speaking of SurgOnc, Dr. Rick Greene discusses with Dr. Mecker G. Möller crucial questions regarding colorectal peritoneal metastasis (CRC-PM) management, particularly concerning the optimal applications of HIPEC in clinical practice, as reported in the article, "Great Debate: Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases—Should It Be Offered?"

On this episode of America at Night with Rich Valdés, Congressman Andy Harris (R-MD) joins the show to discuss the end of the government shutdown, the Supreme Court's decision on late mail-in ballots, and growing calls to deport Rep. Ilhan Omar. Then, political scholar and author Dr. Carol Swain shares how she won a powerful debate on Black Lives Matter at the prestigious Cambridge Union, challenging mainstream narratives with facts and conviction. Finally, Big Brother star and author Gina Marie stops by to talk about her new book, Stanley 3.0, and the life lessons behind her inspiring story. Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode, Isabella Matamoros, a first-year student at the University of Georgia, sits down with some of NHI's recent Great Debate participants. In the first segment, Isa interviews Emma Wulff to discuss her experience as an Oratory finalist at the 2025 Northeast Great Debate at Saint Francis University in Loretto, Pennsylvania. In the second segment, Isa talks with Andrew Mefrige, Jacob Suarez, and Sophia Tabuenca, participants of the 2025 Texas Great Debate hosted by Austin College in Sherman, Texas. Our participants got to share their first-hand experiences, their new-found strengths, and what they look forward to in 2026. Host & audio editing: Isabella Matamoros, Podcast art: Diego Garcia, Music: Zaiden WorleyTo learn more about the Great Debates, visit: www.nationalhispanicinstitute.org/great-debate

9 More Attempts To Disprove God Here are 9 more attempts by Dr. Gordon Stein to levy his critiques against traditional arguments for God. With all 11 of them, has there been any that have addressed the claims presented by Dr. Greg Bahnsen? What do you think about these critiques? TIMELINE: 00:00 - Introduction 01:54 - The Revealed Theology Argument Taken Down - No Circles 02:57 - Presuppositional Christian Responds - Two Issues 06:20 - The Miracles Argument Taken Down - No Begging Allowed 07:56 - Presuppositional Christian Responds - Only Atheists Can Beg It Seems 10:35 - The Perfect God Argument Taken Down - Existence First 12:26 - Presuppositional Christian Responds - Agrees With Being Careful 13:37 - The Moral Argument Taken Down - Not Need & Different Values 15:29 - The Wish Argument Taken Down - Nice But Not True 16:21 - The Faith Argument Taken Down - No Reason Unless Reason 17:24 - Presuppositional Christian Responds - All Reason Rests On Faith 20:09 - The Religious Experience Argument Taken Down - It's Only Feelings 21:56 - Presuppositional Christian Responds - Agree But For Different Reasons 22:30 - The Pascal's Wager Argument Taken Down - How To Pick? 25:06 - Conclusion BOOK LINKS: The Great Debate - Does God Exist? - Edited and Commentary by Joshua Pillows Debate Transcript Video The Bahnsen Institute       All episodes, short clips, & blog - https://www.cavetothecross.com

In this episode of Louisiana Unfiltered, Kiran Chawla sits down with Attorney Robert Aguiluz as they discuss the proposed merger of Emergency Medical Services (EMS) and the Baton Rouge Fire DepartmentChapters0:19 The Great Debate 01:43  Robert Aguiluz Joins Kiran Chawla27:43 Legal Battles Ahead35:11 EMS Employee Concerns37:01 Job Security at Risk41:43 Chris Landry's Role52:44 Voices of the Paramedic AssociationLocal Sponsors for this episode include:Neighbors Federal Credit Union:Another Chance Bail Bonds:Dudley DeBosier Injury LawyersSound and Editing for this audio podcast by Envision Podcast Production:#louisianaunfiltered  #kiranchawla #podcast  #unfilteredwithkiran #news  #louisiana  #ems #brfd  

In somewhat of an unconventional "studio" setting - namely a gutted former restaurant under renovation and equipped with only a table, a few folding chairs, a cooler of beer and an extension cord - 6 fellow music lovers travelled from across the Eastern Seaboard to Downtown Huntington to discuss and debate a subject that has been the hot topic among the group for over 6 years.  "What are the Top-5 greatest American rock-&-roll bands of all time."  Key word - American.No Stones.  No Beatles.  No U2.  No Led Zeppelin (#sorrymeyers).  The criteria as to what makes a band authentically American was that every band member, without exception, must have been born in the United States.  No Metallica (#sorryhanna).After the rules of engagement were spelled out, the conversation that ensued over the next 50+ minutes was as spirited and riveting as any I've hosted in any prior episode.  Enjoy the energy that flowed amongst my co-host, Rob "Monkey Man" Diestel, and his "Boys from Bergen" - Nick Halaby, Lewis Meyers, and Matt Hanna.  Special cameo appearance at the end by our sound engineer, none other than founding member and frontman of Huntington's own Bogmen, Billy Campion.  Thanks again for herding us cats and taking such good care of us, Billy!So join us, and let's see where the energy takes us!Midnight Flyer / Eagleshttps://music.apple.com/us/album/midnight-flyer/635765828?i=635765933The Boys of Summer / Don Henleyhttps://music.apple.com/us/album/the-boys-of-summer-remastered-2024/1761230483?i=1761230752Everyday People / Sly & the Family Stonehttps://music.apple.com/us/album/everyday-people/193125445?i=193126391Truckin' / Grateful Deadhttps://music.apple.com/us/album/truckin-live/307793560?i=307793566Kokomo / Beach Boys https://music.apple.com/us/album/kokomo/1617206809?i=1617208420Don't Believe the Hype / Public Enemy https://music.apple.com/us/album/dont-believe-the-hype/1440837788?i=1440837952Crosseyed & Painless / Phishhttps://music.apple.com/us/album/crosseyed-and-painless/396463671?i=396463832The Weight / Aretha https://music.apple.com/us/album/the-weight/934618187?i=934618225Free Bird / Lynyrd Skynyrd https://music.apple.com/us/album/free-bird-live-at-the-fox-theater-1976/1413948379?i=1413948706 https://www.facebook.com/groups/1983015048745357

Join Mike and DJ for a Great Debate: SOUND MONEY OR SLAVERY? feat. Andrew Page (Strawman) and Scott Phillips (Motley Fool). - Understanding Bitcoin's Adoption Curve- 2% or 5% Bitcoin TAM- Is Bitcoin Christianity?- Knightian Uncertainty- -Follow Andrew on X/Twitter: https://x.com/sage_simianFollow Scott on X/Twitter: https://x.com/TMFScottP- -WHO CONTROLS THE MONEY? https://learn.hardblock.com.au/a-history-of-banking-in-australia/WHY NOT SAVE IN BITCOIN?https://www.hardblock.com.au/dca-calculatorLEARNING BITCOIN? Go from Zero to Hero with HardBlock Learn: www.learn.hardblock.com.auGET BITCOIN, EASY. DOWNLOAD OUR FREE BITCOIN BOOK: https://content.hardblock.com.au/easybitcoinbookSIGN-UP and START STACKING SATS TODAY: www.hardblock.com.au/join/ozbitcoinpodThanks for listening. Got a question? Got a comment? Is there something you'd like us to cover on the pod? Let us know: Tweet us on X @HardBlockBTC or Email: info@australianbitcoinpodcast.com.au

You've heard of East Coast vs. West Coast — but forget all that. This week, we're settling the real rivalry: the Midwest vs. the Pacific Northwest. Shea and Jody of Rainy Day Rabbit Holes, the podcast that uncovers the wild, weird, and wonderful hidden stories of the Pacific Northwest and beyond, join Trevin and Amanda for a four-round battle of regional pride, petty chaos, and pointless competition. Before the main event, our hosts bring their dreadful dilemmas, ranging from awkward public encounters with subtly racist strangers, being too busy for dog playdates, and making retirement plans far too early — plus, Amanda spots our modern-day muse, Chappell Roan, out in the wilds of Kansas City. Then, it's time for the Great Debate — a showdown across four over-the-top rounds: ⚔️ Round One: The Great Debate – Each team makes an absurdly passionate case for their homeland, backed by one bizarre local legend. From the Midwest's failed utopia of Fordlandia to Oregon's infamous exploding whale, chaos is the only constant.

The Great Midwest vs. PNW Debate (Feat. Rainy Day Rabbit Holes) You’ve heard of East Coast vs. West Coast — but forget all that. This week, we’re settling the real rivalry: the Midwest vs. the Pacific Northwest. Shea and Jody of Rainy Day Rabbit Holes, the podcast that uncovers the wild, weird, and wonderful hidden stories of the Pacific Northwest and beyond, join Trevin and Amanda for a four-round battle of regional pride, petty chaos, and pointless competition. Before the main event, our hosts bring their dreadful dilemmas, ranging from awkward public encounters with subtly racist strangers, being too busy for dog playdates, and making retirement plans far too early — plus, Amanda spots our modern-day muse, Chappell Roan, out in the wilds of Kansas City. Then, it’s time for the Great Debate — a showdown across four over-the-top rounds: Round One: The Great Debate – Each team makes an absurdly passionate case for their homeland, backed by one bizarre local legend. From the Midwest’s failed utopia of Fordlandia to Oregon’s infamous exploding whale, chaos is the only constant.

(0:00-10:12) Happy All-Star Day! Kevin Cooney joins us for the first hour! Have you see enough this season to say the Eagles are truly favorites?(10:12-16:43) Is your biggest concern Eagles enough to the team back?(16:43-29:04) The Great debate between John Kincade & Kevin Cooney on Rob Thomson, Nick Sirianni, Baseball Writers Hall of Fame, Bruce Springsteen, & Notre Dame fandom from Philly (29:04-36:48) They guys react to the Cowboys loss on MNF & Jerry Jones contradicted his own comments from before and after the game Please note: Timecodes may shift by a few minutes due to inserted ads. Because of copyright restrictions, portions—or entire segments—may not be included in the podcast.For the latest updates, visit the show page Kincade & Salciunas on 975thefanatic.com. Follow 97.5 The Fanatic on Twitter, Facebook, and Instagram. Watch our shows on YouTube, and subscribe to stay up-to-date with all the best moments from Philly's home for sports!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Atheist Attempts To Disprove God It's now Dr. Gordon Stein's turn in the debate. This atheist attempts to disprove God in 11 different ways. However, what seems to happen here is the use of an odd definition for God and an actual need for one more argument - the one Dr. Bahnsen uses. TIMELINE: 00:00 - Introduction 05:59 - Dr. Gordon Stein's Opening Statement - On Facts 07:01 - Atheist Stein's Definition Of Atheism 09:27 - Atheist Stein's Definition Of God 11:45 - Atheist Takes Down 11 Proofs For The Existence Of God 13:38 - The Cosmological Argument Taken Down - The Uncaused Universe 16:40 - Joshua Pillows Commentary Against Stein's Presentation 21:14 - Joshua Pillows Commentary Against The Cosmological Argument 23:55 - The Design Argument Taken Down - The Undesigned Universe 26:29 - The Life Argument Taken Down - The Unmoved Life 28:42 - Joshua Pillow Commentary Against Stein's Induction 31:54 - Conclusion LINK: 30:19 - Dr. Jason Lisle Does Some Science BOOK LINKS: The Great Debate - Does God Exist? - Edited and Commentary by Joshua Pillows Debate Transcript Video The Bahnsen Institute       All episodes, short clips, & blog - https://www.cavetothecross.com

Scott, Paul, and Lauren discuss miscommunications, Paul’s DVDs, and pics with celebs before playing The Great Debate. Send Threetures and emails to threedomusa@gmail.com.Leave us a voicemail asking us a question at hagclaims8.comFollow us on Instagram @ThreedomUSA.Unlock every episode of THREEDOM and THREEMIUM, ad-free, on cbbworld.comGrab some new Threedom merch at cbbworld.com/merchSee omnystudio.com/listener for privacy information.

Host Gerard Slobogean, MD talks with Raymond Pensey, MD and Phillip Lam, MD about treating the older patient faced with limb salvage vs. amputation.

3 Important Claims In The Great Debate Here is Dr. Greg Bahnsen's 3 important claims in the Great Debate. The first two are there to sweep away a lot of confusion Dr. Stein and other atheists have when it comes to the type of argumentation presuppositionalists use. Unfortunately, Dr. Stein didn't seem to be prepared to actually engage in that type of debate as we'll see in the coming weeks. TIMELINE: 00:00 - Introduction 01:36 - The 3 Claims Of Bahnsen's Opening Statement 06:00 - Cracker's Don't Matter! - The Nature Of Evidence Between Christians & Atheists 11:12 - Presuppositional Conflict Of Worldviews 26:54 - The Transcendental Argument For God As A Positive Claim 31:49 - Conclusion BOOK LINKS: The Great Debate - Does God Exist? - Edited and Commentary by Joshua Pillows Debate Transcript Video The Bahnsen Institute       All episodes, short clips, & blog - https://www.cavetothecross.com

Welcome to Caching in the NorthWest! This is THE podcast from the birthplace of geocaching, right here in the great Pacific NorthWest.  It's Thursday at 7PM Pacific and we are going to talk about geocaches and geocachers from here and around the globe. So while you're crying in your Cheerios about the Mariners, we'll be Caching in the NorthWest. We want you to call in your Geocache Log of the Week! Send an email to feedback@CachingNW.com, call into 253-693-TFTC. Call us with your feedback at (253) 693-TFTC Or visit the website at https://CachingNW.com

Setting The Stage We open our 14th book by setting the stage for The Great Debate. We cover the Forward by Eli Ayala and Preface by Joshua Pillows, who give the background for the debate and speakers. Then we dive into Dr. Greg Bahnsen's opening statement, where he uses most of his time covering what the debate is and what it isn't. He also covers why he's going to talk about the Christian form of theism and how the debate can be an objective matter and not a subjective one. TIMELINE: 00:00 - Introduction 03:39 - Forward By Eli Ayala (Revealed Apologetics) 09:07 - Preface To The Debate 14:56 - The Book's Format 16:34 - Bahnsen's Opening - Setting The Stage For The Debate 17:40 - 3 Reasons Why To Argue For Christian Theism Not General Theism 21:09 - Defining Your Terms & The Debate Is & Isn't 22:34 - 3 Reasons To Focus On Objective Matters, Not Subjective 26:32 - The Nature Of The Debate 29:20 - Conclusion BOOK LINKS: The Great Debate - Does God Exist? - Edited and Commentary by Joshua Pillows Debate Transcript Video The Bahnsen Institute       All episodes, short clips, & blog - https://www.cavetothecross.com

Weekend Edition for October 18-19, 2025 Show Notes: Germany / Switzerland - Study Tour  Support 1517 Podcast Network 1517 Podcasts 1517 on Youtube 1517 Podcast Network on Apple Podcasts 1517 Events Schedule 1517 Academy - Free Theological Education What's New from 1517: Untamed Prayers: 365 Daily Devotions on Christ in the Book of Psalms by Chad Bird https://www.amazon.com/Untamed-Prayers-Devotions-Christ-Psalms/dp/1964419263 Remembering Your Baptism: A 40-Day Devotional by Kathryn Morales https://shop.1517.org/collections/new-releases/products/9781964419039-remembering-your-baptism Sinner Saint by Luke Kjolhaug https://shop.1517.org/products/9781964419152-sinner-saint The Impossible Prize: A Theology of Addiction by Donavan Riley https://shop.1517.org/products/9781962654708-the-impossible-prize More from the hosts: Dan van Voorhis SHOW TRANSCRIPTS are available: https://www.1517.org/podcasts/the-christian-history-almanac CONTACT: CHA@1517.org SUBSCRIBE: Apple Podcasts Spotify Stitcher Overcast Google Play FOLLOW US: Facebook Twitter Audio production by Christopher Gillespie (outerrimterritories.com).

The Great Debate Series: Best play that came in a losing effort. I Bogusch brings the crew a gift from The Keys...kinda. I Callers phone in with their suggestions for The Great Debate.

Join Alex Crespo, MD and Hassan Mir, MD as they debate the role of fibular IM nailing in the treatment of ankle fractures. Click for the abstract link. For additional educational resources visit OTA.org  

Book 14 Announcement For our 14th book, we dive into one of the great moments for presuppositional apologetics. The debate between Greg Bahnsen and Gordon Stein in 1985 is a seminal watershed moment in apologetics history. Join us, starting next week, as we walk through the debate with the book The Great Debate edited and commented on by Joshua Pillows. BOOK LINKS: The Great Debate - Does God Exist? - Edited and Commentary by Joshua Pillows Debate Transcript Video The Bahnsen Institute       All episodes, short clips, & blog - https://www.cavetothecross.com

Ready to finally Settle the Great Debate Over Bugs and Spikes (or at least get a coherent philosophy)?  We're diving into the details with high-impact takeaways! Stop the confusion and start delivering—we'll clarify the essential difference between a bug, a defect, and technical debt, giving you the clarity to triage like a pro.  Learn exactly why spikes aren't just a waste of time (and why you definitely don't need a spike for every user story).  Get ready for actionable advice to maximize transparency, minimize risk, and ensure your team's velocity stays honest and on track!  Tune in for practical strategies you can use in your next Sprint.

Willie Geist joins Jenna for a game of The Great Debate. Also, Aubrey Plaza discusses her new children's book, “Luna and the Witch Throw a Halloween Party.” Plus, dating advice influencer Laurie Cooper joins for a Martini Meetup. And, Today Food culinary producer Anthony Contrino celebrates National Cake Decorating Day. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Guest - Seattle City Council President Sara Nelson // Nelson opponent, Dionne Foster drops out of “The Great Debate” on Saturday Oct. 11th // Sara Nelson is fighting to keep her Seattle City Council seat // ‘We can be compassionate without being chumps’: Councilmember Sara Nelson responds to Harrell’s viral embarrassment //Sara Nelson // LETTERS

TMPT Special Feature show today with John Poz, welcomes in historian and podcaster, Ray Russell for The Great Debate on Hulk Hogan. Its Hulk Hogan vs the World! Who really is behind the success of the WWF during its "Golden Era" (Hogan Era)? Hulk Hogan or the rest of the WWF? Host John Poz and Ray will talk Vince McMahon, Roddy Piper, Macho Man, Ultimate Warrior, Andre The Giant, Paul Orndorff, and so much more!Follow us on Twitter and IG @TwoManPowerTripStore - Teepublic.com/stores/TMPTtwomanpowertrip.dashery.com

In this episode, Mike and Chris debate a recent article in All About Beer decrying the death of the beer bar at the hands of the brewery tap room. But there's a twist: Chris and Mike decide to switch places, with Chris advocating for brewery tap rooms, and Mike championing specialty beer bars. Link to Andy Crouch's article: Here*We're Looking for a Dungeon Master! * Email Eletters to: Insiders@craftbeertemple.comMailing address: The Beer Temple 3173 N. Elston Ave. Chicago, IL 60618Intro/Outro Music: Gorilla Meat by Jogger UYD4L!

It's a debate that happens frequently in Black households with a college-bound student — to attend a historically Black college or university (HBCU) or a predominately white institution (PWI)? Which type of college experience is better for an African-American student? Does legacy, smaller classes and culture override upgraded facilities, name recognition and a potentially wider professional network? We'll talk about the issue with two recent graduates who took very different higher educational paths, along with the director of counseling from a local high school who advises students on both options.

Juan and a panel of guests compare the legendary careers of Bret Hart and Shawn Michaels. #WWE

This week's Great Debate regarding what the most 'likable' sports team of all time is I Maggie and Perloff react LIVE to Dillon Gabriel being named the Browns' starting QB I M&P take YOUR calls on today's Great Debate

Maggie and Perloff close Wednesday's show with Matt Mosley of The Doomsday Podcast I More calls on the Great Debate about the most 'likable' sports team ever

What a great problem to have! Naming the Mariners #1 starter: the great debate! Who should get the nod in game 1 on Saturday? :30- Happy Humpday! Nick Emmanwori is expected to play on Sunday, how big of an impact can he have on this defense? :45- We close out the show with one last thing! See omnystudio.com/listener for privacy information.

What a great problem to have! Naming the Mariners #1 starter: the great debate! Who should get the nod in game 1 on Saturday? :30- Happy Humpday! Nick Emmanwori is expected to play on Sunday, how big of an impact can he have on this defense? :45- We close out the show with one last thing!

Hour 3: The guys debate if Aaron Judge is deserving of the MVP or if it should go to Cal Raleigh. All that and more.

Watch the YouTube version of this episode HEREAre you a lawyer looking for some AI hacks? In this episode of The Guild Live Show, Tyson explores the latest in AI and tech. He demos String, a new text-to-agent AI platform for building automated workflows, and reviews Google's updated Notebook LM, highlighting its new flashcards, quizzes, and multimedia study tools.Tyson talks about the text-to-agent AI platform, String which is a workflow builder. The tool is an autonomous bot that can execute tasks and run automations. You type in what you want and it builds it for you, which is unique compared to other AI tools. For lawyers it can be a game changer. For Tyson, he created a workflow using personal injury cases to draft a comprehensive report.Tyson shares a workflow hack for lawyers involved with project management. When you create a project, you can automatically create a link connecting it to Google Contacts. That way you connect a project with the contact information for a client. So, when you start typing the client's name, the email for the project comes up and you can continue working on it if you have stepped away. It is a great life hack to save you some time!Listen in to learn more!1:18 The introduction of String, a text-to-agent AI platform7:59 Discussion of new features in Google's Notebook LM25:59 A workflow hack for project management28:08 The value of adaptable employeesTune in to today's episode and checkout the full show notes here. 

In this episode, Eli is joined by Joshua Pillows to discuss the release of the new book "The Great Debate" (Bahnsen vs. Stein) does God Exist?

In this episode, Lady Landlords founder, Becky Nova…breaks down the pros and cons of buying rental properties locally vs. out of state. The episode highlights that success depends on aligning your choice with your budget, time, risk tolerance, and long-term goals. There's no “one right way,” only what works best for you. Let's dive into what that is!Interested in working with Lady Landlords?  Email Becky@Lady-landlords.com. ===

Join host Dr. Michael Blankstein as he and Professor Rodrigo Pesantez debate the treatment options for Vancouver B2 periprosthetic fractures and stress the importance of knowing how and when to fix or revise. For additional educational resources visit OTA.org

Join Gary and Russ Breault as they discuss and defend Creationism over the evolutionary theory.

Dr. Greg Gaski hosts an engaging conversation with Drs. Peter Mittwede, and Rob Wetzel on treatment protocols following periarticular fracture repair including controversial topics with limited high-level evidence: pelvis, acetabulum, distal femur, tibial plateau, and pilon fractures. For additional educational resources visit OTA.org

Dr. Joseph Patterson moderates another lively debate with Dr. Josh Blomberg and Dr. Charalampos Zalavras on the topic of Operative versus Nonoperative Treatment of Humeral Shaft Fractures. For additional educational resources visit OTA.org

Lead True Crimecast writer Mackenzie joins this Patreon exclusive episode to debate Jamie on Scott Peterson's guilt. Could he really be innocent? And if he is, can Jamie be convinced of that? --For early, ad free episodes and monthly exclusive bonus content, join our Patreon!

For the 2025 Emmy Awards, several worthy nominees are debated by podcast hosts Bubba & Catfish. If you're a fan of their old-school petty sniping at each other, you'll love this one. Emmy voter Catfish seemingly closes his eyes to pick terrible winners. With the patience of a saint, Bubba listens to the inane choices before finally blowing a gasket about an hour into the pod. #Emmys #EmmyAwards #Emmys2025 #EmmyNoms #nominations #nominees #PrimetimeEmmyAwards  Discussion: 00:00 Intro 04:55 Lead Actor in a Comedy Series 08:48 Lead Actor in a Drama Series 13:51 Lead Actor in a Limited or Anthology Series or Movie 17:29 Lead Actress in a Comedy Series 21:21 Lead Actress in a Drama Series 23:23 Lead Actress in a Limited or Anthology Series or Movie 25:13 Supporting Actor in a Comedy Series 28:30 Supporting Actor in a Drama Series 31:25 Supporting Actor in a Limited or Anthology Series or Movie 33:55 Supporting Actress in a Comedy Series 37:01 Narrator  38:07 Character Voice Over Performance 40:01 Supporting Actress in a Drama Series 41:49 Supporting Actress in a Limited or Anthology Series or Movie 43:46 Guest Actor Comedy 45:38 Guest Actor Drama 48:25 Guest Actress Comedy 49:46 Guest Actress Drama 52:18 Performer in a Short Form Series 53:55 Host for a Reality Program 55:28 Host for a Game Show 56:55 Outstanding Comedy Series 58:08 Outstanding Drama Series 1:04:03 Outstanding Limited or Anthology Series 1:06:02 Outstanding Television Movie 1:06:43 Outstanding Talk Series 1:07:19 Outstanding Scripted Variety Series 1:08:13 Outstanding Live Variety Special 1:10:19 Outstanding Vareity Special Pre-Recorded 1:10:50 Outstanding Short Form Special 1:11:26 Outstanding Short Form Non Fiction 1:12:24 Outstanding Hosted Non-Fiction Special 1:13:31 Outstanding Structured Reality Show 1:14:18 Outstanding Unstructured Reality Show 1:15:15 Outstading Reality Competition Program 1:16:57 Outstanding Game Show Outstanding Lead Actor in a Comedy Series Adam Brody – Nobody Wants This as Noah Roklov (Netflix) Seth Rogen – The Studio as Matt Remick (Apple TV+) Jason Segel – Shrinking as Jimmy Laird (Apple TV+) Martin Short – Only Murders in the Building as Oliver Putnam (Hulu) Jeremy Allen White – The Bear as Carmen "Carmy" Berzatto (FX) Outstanding Lead Actor in a Drama Series Sterling K. Brown – Paradise as Xavier Collins (Hulu) Gary Oldman – Slow Horses as Jackson Lamb (Apple TV+) Pedro Pascal – The Last of Us as Joel Miller (HBO) Adam Scott – Severance as Mark Scout (Apple TV+) Noah Wyle – The Pitt as Dr. Michael "Robby" Robinavitch (HBO Max) Outstanding Lead Actor in a Limited or Anthology Series or Movie Colin Farrell – The Penguin as Oswald "Oz" Cobb / The Penguin (HBO) Stephen Graham – Adolescence as Eddie Miller (Netflix) Jake Gyllenhaal – Presumed Innocent as Rozat "Rusty" Sabich (Apple TV+) Brian Tyree Henry – Dope Thief as Ray Driscoll (Apple TV+) Cooper Koch – Monsters: The Lyle and Erik Menendez Story as Erik Menendez (Netflix) Outstanding Lead Actress in a Comedy Series Uzo Aduba – The Residence as Cordelia Cupp (Netflix) Kristen Bell – Nobody Wants This as Joanne (Netflix) Quinta Brunson – Abbott Elementary as Janine Teagues (ABC) Ayo Edebiri – The Bear as Sydney "Syd" Adamu (FX) Jean Smart – Hacks as Deborah Vance (HBO Max) Outstanding Lead Actress in a Drama Series Kathy Bates – Matlock as Madeline "Matty" Matlock / Madeline Kingston (CBS) Sharon Horgan – Bad Sisters as Eva Garvey (Apple TV+) Britt Lower – Severance as Helly R. (Apple TV+) Bella Ramsey – The Last of Us as Ellie (HBO) Keri Russell – The Diplomat as Katherine "Kate" Wyler (Netflix) Lead Actress in a Limited or Anthology Series or Movie Cate Blanchett – Disclaimer as Catherine Ravenscroft (Apple TV+) Meghann Fahy – Sirens as Devon DeWitt (Netflix) Rashida Jones – Black Mirror: "Common People" as Amanda Waters (Netflix) Cristin Milioti – The Penguin as Sofia Falcone / Sofia Gigante / The Hangman (HBO) Michelle Williams – Dying for Sex as Molly Kochan (FX) Outstanding Supporting Actor in a Comedy Series Ike Barinholtz – The Studio as Sal Saperstein (Apple TV+) Colman Domingo – The Four Seasons as Danny (Netflix) Harrison Ford – Shrinking as Dr. Paul Rhoades (Apple TV+) Jeff Hiller – Somebody Somewhere as Joel (HBO) Ebon Moss-Bachrach – The Bear as Richard "Richie" Jerimovich (FX) Michael Urie – Shrinking as Brian (Apple TV+) Bowen Yang – Saturday Night Live as various characters (NBC) Outstanding Supporting Actor in a Drama Series Zach Cherry – Severance as Dylan George (Apple TV+) Walton Goggins – The White Lotus as Rick Hatchett (HBO) Jason Isaacs – The White Lotus as Timothy Ratliff (HBO) James Marsden – Paradise as President Cal Bradford (Hulu) Sam Rockwell – The White Lotus as Frank (HBO) Tramell Tillman – Severance as Seth Milchick (Apple TV+) John Turturro – Severance as Irving Bailiff (Apple TV+) Outstanding Supporting Actor in a Limited or Anthology Series or Movie Javier Bardem – Monsters: The Lyle and Erik Menendez Story as José Menendez (Netflix) Bill Camp – Presumed Innocent as Raymond Horgan (Apple TV+) Owen Cooper – Adolescence as Jamie Miller (Netflix) Rob Delaney – Dying for Sex as Neighbor Guy (FX) Peter Sarsgaard – Presumed Innocent as Tommy Motto (Apple TV+) Ashley Walters – Adolescence as DI Luke Bascombe (Netflix) Outstanding Supporting Actress in a Comedy Series Liza Colón-Zayas – The Bear as Tina Marrero (FX) Hannah Einbinder – Hacks as Ava Daniels (HBO Max) Kathryn Hahn – The Studio as Maya Mason (Apple TV+) Janelle James – Abbott Elementary as Ava Coleman (ABC) Catherine O'Hara – The Studio as Patty Leigh (Apple TV+) Sheryl Lee Ralph – Abbott Elementary as Barbara Howard (ABC) Jessica Williams – Shrinking as Gaby Evans (Apple TV+) Outstanding Supporting Actress in a Drama Series Patricia Arquette – Severance as Harmony Cobel (Apple TV+) Carrie Coon – The White Lotus as Laurie Duffy (HBO) Katherine LaNasa – The Pitt as Charge Nurse Dana Evans (HBO Max) Julianne Nicholson – Paradise as Samantha "Sinatra" Redmond (Hulu) Parker Posey – The White Lotus as Victoria Ratliff (HBO) Natasha Rothwell – The White Lotus as Belinda Lindsey (HBO) Aimee Lou Wood – The White Lotus as Chelsea (HBO) Outstanding Supporting Actress in a Limited or Anthology Series or Movie Erin Doherty – Adolescence as Briony Ariston (Netflix) Ruth Negga – Presumed Innocent as Barbara Sabich (Apple TV+) Deirdre O'Connell – The Penguin as Francis Cobb (HBO) Chloë Sevigny – Monsters: The Lyle and Erik Menendez Story as Kitty Menendez (Netflix) Jenny Slate – Dying for Sex as Nikki Boyer (FX) Christine Tremarco – Adolescence as Manda Miller (Netflix) Outstanding Comedy Series Abbott Elementary (ABC) The Bear (FX) Hacks (HBO Max) Nobody Wants This (Netflix) Only Murders in the Building (Hulu) Shrinking (Apple TV+) The Studio (Apple TV+) What We Do in the Shadows (FX) Outstanding Drama Series Andor (Disney+) The Diplomat (Netflix) The Last of Us (HBO) Paradise (Hulu) The Pitt (HBO Max) Severance (Apple TV+) Slow Horses (Apple TV+) The White Lotus (HBO) Outstanding Limited or Anthology Series Adolescence (Netflix) Black Mirror (Netflix) Dying for Sex (FX) Monsters: The Lyle and Erik Menendez Story (Netflix) The Penguin (HBO) Outstanding Reality Competition Program The Amazing Race (CBS) RuPaul's Drag Race (MTV) Survivor (CBS) Top Chef (Bravo) The Traitors (Peacock) Outstanding Talk Series The Daily Show (Comedy Central) Jimmy Kimmel Live! (ABC) The Late Show with Stephen Colbert (CBS) Outstanding Scripted Variety Series Last Week Tonight with John Oliver (HBO) Saturday Night Live (NBC)     

Gregg Tawney and Rich Hartman discuss the tactical, legal and practical considerations surrounding the "positive control" release and the release from a distance. This is a must watch for any handler, trainer and supervisor. Thank you to our sponsors: Ray Allen Mfg. - Rayallen.com Inukshuk Performance Dog food - INUKSHUKPRO.com Black Jacks Leather - BlackJacksleather.com Sauna Box - Saunabox/k9.com Key word "K9" for discount Connect with Us: Instagram: @policek9radio663 Email: Trainers@Dtack9.com